Order results by:
| Issue | Title | |
| Vol 13, No 6 (2021) | Multicenter, randomized, double-blind study of the efficacy and safety of prolonged release tolperisone hydrochloride 450 mg (Mydocalm® Long, once daily) and tolperisone hydrochloride 150 mg (three times daily) for acute non-specific lower back pain | Abstract similar documents |
| V. A. Parfenov, E. I. Bogdanov, V. B. Laskov, N. S. Makarov, N. V. Pisova, E. A. Salina, Zh. Yu. Chefranova, L. V. Chichanovskaya | ||
| "... and safety of the new dosage form of PRTH 450 (Mydocalm® Long, once a day) in comparison with TH 150 ..." | ||
| Vol 12, No 6 (2020) | Efficacy and safety of antipsychotics in adolescents with an acute psychotic episode in relation to the activity of CYP3A and CYP2D6 isoenzymes | Abstract similar documents |
| D. V. Ivashchenko, A. S. Osipov, E. V. Nazarova, M. A. Ovchinnikova, N. I. Buromskaya, V. V. Smirnov, P. V. Shimanov, R. V. Deitch, T. A. Fainshtein, E. N. Shagovenko, K. A. Akmalova, A. A. Kachanova, E. A. Grishina, L. M. Savchenko, Yu. S. Shevchenko, D. A. Sychev | ||
| "... Antipsychotics are a first-line treatment for psychotic disorders. The cytochrome P450 isoenzymes ..." | ||
| Vol 12, No 2 (2020) | Pharmacogenetics of the safety of phenazepam in alcohol withdrawal syndrome: haplotype and combinatorial analyses of polymorphic variants in the pharmacokinetic factor genes | Abstract similar documents |
| D. V. Ivashchenko, O. V. Tereshchenko, I. I. Temirbulatov, K. A. Akmalova, E. A. Grishina, M. S. Zastrozhin, L. M. Savchenko, E. A. Bryun, D. A. Sychev | ||
| "... by cytochrome P450 3A (CYP3A) isozymes. Since their substrates have an affinity for P-glycoprotein ..." | ||
| Vol 12, No 1 (2020) | Comparative efficacy and tolerance of centrally acting muscle relaxants in elderly patients with nonspecific musculoskeletal pain | Abstract similar documents |
| R. V. Gorenkov, M. N. Dadasheva, I. A. Zolotovskaya, V. A. Kruglov | ||
| "... ) 150 mg thrice a day; Group 2 used tizanidine 2 mg thrice a day; Group 3 had baclofen 10 mg twice a day ..." | ||
| Vol 12, No 2 (2020) | Efficacy of tolperisone versus meloxicam in the treatment of nonspecific acute neck pain | Abstract similar documents |
| K. V. Skorobogatykh, Yu. E. Azimova | ||
| "... for nonspecific acute neck pain with tolperisone 150 mg/day, followed by dose escalation up to 450 mg/day, versus ..." | ||
| Vol 1, No 2 (2009) | ACUTE BACK PAIN IN THE OUTPATIENT SETTING AND ITS TREATMENT WITH MYDOCALM AND MIRLOX | Abstract similar documents |
| S. V. Verbitskaya, V. A. Parfenov, K. N. Borisov | ||
| "... back pain, 30 patients were treated with mirlox (7,5- 15 mg/day) and 30 patients received mirlox ..." | ||
| Vol 3, No 4 (2011) | Pharmacoeconomic analysis of the use of movalis (meloxicam) in patients with nonspecific back pain | Abstract similar documents |
| O. N. Gerasimova, V. A. Parfenov | ||
| "... The paper analyzes the use of movalis (meloxicam) in 150 patients with nonspecific back pain ..." | ||
| Vol 7, No 3 (2015) | Efficiency of epilepsy treatment in the Moscow Region under the present-day conditions of drug provision | Abstract similar documents |
| Irina Gennadyevna Rudakova, Yu. A. Belova | ||
| "... . частота достижения ремиссии и число респондеров (ответившие на терапию) снизились в 2 раза. Результаты ..." | ||
| Vol 4, No 1 (2012) | New possibilities in the prevention of stroke in atrial fibrillation | Abstract similar documents |
| Vladimir Anatolyevich Parfenov, S V Verbitskaya | ||
| "... the efficacy of the new thrombin inhibitor dabigatran (pradax) in a dose of 150 or 110 mg twice daily ..." | ||
| Vol 10, No 4 (2018) | Pharmacogenetics of schizophrenia in real clinical practice: a clinical case | Abstract similar documents |
| R. F. Nasyrova, N. A. Schnaider, K. O. Mironov, G. A. Shipulin, O. P. Dribnokhodova, E. A. Golosov, M. Yu. Tolmachev, B. V. Andreev, A. A. Kurylev, L. Sh. Akhmetova, О. V. Limankin, N. G. Neznanov | ||
| Vol 9, No 3 (2017) | Clinical results of and prospects for the use of controlled-release antiepileptic drugs: a new once-daily levetiracetam formulation | Abstract similar documents |
| P. N. Vlasov | ||
| Vol 12, No 6 (2020) | Nonsteroidal anti-inflammatory drugs, muscle relaxants, and B-group vitamins in the treatment of lumbar ischialgia | Abstract similar documents |
| V. A. Shirokov, A. V. Potaturko, N. L. Terekhov | ||
| "... -mg tablet daily for 14 days in combination with tolperisone (Calmirex®) as tablets: 150 mg (Day 1 ..." | ||
| Vol 14, No 3 (2022) | The efficacy of ipidacrine in patients with diabetic polyneuropathy | Abstract similar documents |
| P. R. Kamchatnov, E. R. Barantsevich, A. V. Chugunov, A. A. Kabanov, B. A. Abusueva | ||
| "... ) received ipidacrine 20 mg orally 3 times a day for 60 days, patients of the 2nd group (n=17) received ..." | ||
| Vol 6, No 3 (2014) | Myofascial pain: from Virchow's to our days | Abstract similar documents |
| I. V. Egorov | ||
| "... drugs and further to the increase of their doses because the treatment is ineffective. Modern-day ..." | ||
| Vol 14, No 1 (2022) | Treatment of spasticity in patients with the consequences of traumatic brain injury | Abstract similar documents |
| A. P. Kovalenko, I. A. Vozniuk, K. M. Naumov, V. Yu. Lobzin, S. Yu. Kirtaev | ||
| "... with post-traumatic spastic hemiparesis (at least 6 months after the injury) were examined. 450 to 850 U ..." | ||
| Vol 12, No 1 (2020) | The first experience with thrombolytic therapy for cerebral infarction in the Russian Federation after the use of idarucizumab | Abstract similar documents |
| E. V. Pudov, N. N. Sukhacheva, I. S. Petelina | ||
| "... fibrillation (AF) who took dabigatran 110 mg twice a day developed recurrent ischemic stroke (IS) that caused ..." | ||
| Vol 12, No 1 (2020) | Analysis of the association of the PRDM12 gene with pain sensitivity in individuals with psychoactive substance dependence | Abstract PDF (Eng) similar documents |
| E. G. Poltavskaya, D. N. Savochkina | ||
| "... of the mutant A allele (OR, 2.52; 95% confidence interval (CI), 1.42–4.50) of rs10121864 and its homozygous ..." | ||
| Online-first | Analysis of the association of the PRDM12 gene with pain sensitivity in individuals with psychoactive substance dependence | Abstract similar documents |
| E. G. Poltavskaya, D. N. Savochkina | ||
| "... higher among carriers of the mutant A allele (OR=2.52; 95% Cl=1.42–4.50) rs10121864 and its homozygous AA ..." | ||
| Vol 15, No 2 (2023) | Possibilities of multimodal neuroprotection in patients with chronic cerebral ischemia on the background of arterial hypertension and atherosclerosis | Abstract similar documents |
| I. A. Gribacheva, T. F. Popova, E. V. Petrova, A. V. Zvonkova | ||
| "... by drip infusion (500 mg 1 time per day) for 14 days, followed by oral administration of the drug Mexidol ..." | ||
| Vol 12, No 1 (2020) | The efficacy and safety of ethyl methyl hydroxypyridine succinate used as part of sequential therapy in patients with chronic cerebral ischemia | Abstract similar documents |
| V. V. Burdakov, D. V. Krasnykh | ||
| "... and atherosclerosis, who received intravenous Mexidol® administered dropwise at a dose of 500 mg once a day for 14 ..." | ||
| Vol 13, No 2 (2021) | Actovegin use in patients with cognitive impairment after coronavirus infection (COVID-19) | Abstract similar documents |
| V. A. Kutashov | ||
| "... and 152 women) – were prescribed with actovegin 400 mg 3 times a day in addition to the baseline therapy ..." | ||
| Vol 14, No 2 (2022) | Possibilities nootropic drugs in non-demented patients with vascular cognitive disorders | Abstract similar documents |
| M. N. Dadasheva, R. V. Gorenkov, V. A. Kruglov, K. N. Dadasheva, D. I. Lebedeva | ||
| "... impairment (VCI). Patients and methods. The study included 150 patients with VCI that does not meet dementia ..." | ||
| Vol 15, No 6 (2023) | In-hospital mortality in patients with ischemic stroke and a large cerebral artery occlusion, who underwent mechanical thrombectomy | Abstract similar documents |
| D. M. Murtazalieva, A. R. Zakaryaeva, M. A. Zolotov | ||
| "... on the first day, on days 2–3 and also on days 4–7, while no differences in mortality were observed after ..." | ||
| Vol 16, No 3 (2024) | Therapeutic outcomes in patients with acute non-specific (musculoskeletal) pain according to the FORTE (ФОРТЕ) observational study | Abstract similar documents |
| V. A. Parfenov | ||
| "... the medication Nalgesin® forte 550 mg 1–3 times a day for pain relief; the medication was discontinued when ..." | ||
| Vol 11, No 3 (2019) | Treatment of patients with acute and subacute lumbodynia and lumbar ischialgia | Abstract similar documents |
| V. A. Parfenov, A. I. Isaikin, T. I. Kuzminova, O. A. Chernenko, O. V. Milovanova, A. V. Romanova, N. D. Samkhaeva, Yu. M. Shor | ||
| "... .5%), and piriformis syndrome and SIJ injury (2.5%). The duration of treatment averaged 11.0±2.4 days. By the end ..." | ||
| Vol 16 (2024): (Suppl. 2) | Analysis of the experience with once-weekly intramuscular administration of interferon beta-1a in the Russian population of patients with relapsing-remitting multiple sclerosis | Abstract similar documents |
| F. A. Khabirov, E. V. Granatov, A. Ya. Dykhanov, T. I. Khaibullin | ||
| "... и безопасность применения препарата интерферона бета-1а для внутримышечного введения один раз в ..." | ||
| Vol 11, No 4 (2019) | Mathematical modeling of ischemic stroke | Abstract similar documents |
| V. I. Ershov, A. N. Chirkov, A. P. Gonchar-Zaykin, S. N. Lyashchenko, T. Yu. Lozinskaya, N. V. Gumalatova, G. E. Kuznetsov, L. R. Tenchurina | ||
| "... in the acutest period of severe ischemic stroke (IS). Patients and methods. A total of 150 patients with severe ..." | ||
| Vol 5, No 2 (2013) | Neurasthenia: State-of-the-art and therapeutic approaches | Abstract similar documents |
| Leonid Semenovich Chutko, S Yu Surushkina, I S Nikishena, E A Yakovenko, T I Anisimova | ||
| "... as two administrations for 10 days (5 days at a 2-day interval). The results of therapy were assessed ..." | ||
| Vol 10, No 3 (2018) | The level of interleukin-6 in acute ischemic stroke: effect on the rate of recovery in patients and on the severity of neurological defect | Abstract similar documents |
| S. P. Sergeeva, А. А. Savin, I. D. Breslavich, P. F. Litvitsky, V. V. Arkhipov | ||
| "... levels on days 1, 7, and 21 after onset of IS. An enzyme immunoassay (EIA) was used to measure IL-6 ..." | ||
| Vol 14, No 5 (2022) | Results of ELBRUS clinical non-interventional study | Abstract similar documents |
| D. O. Rozhkov, K. V. Shevtsova, V. V. Grinyuk, V. A. Parfenov | ||
| "... day in patients with chronic non-specific low back pain (CNSLBP). Patients and methods. The study ..." | ||
| Vol 3, No 1 (2011) | Current aspects of the epidemiology and treatment of chronic brain ischemiain the presence of essential hypertension (results of the CALIPSO program) | Abstract similar documents |
| E. I. Chukanova | ||
| "... . The patients received dropwise intravenous Cavinton as infusions within the first week (25 mg on days 1 to 4 ..." | ||
| Vol 15, No 4 (2023) | Evaluation of pharmacokinetic parameters, safety and tolerability of single and multiple doses of Vespireit®: results of phase I clinical trial. | Abstract similar documents |
| O. D. Ostroumova, M. L. Maksimov, M. V. Zamergrad, V. A. Parfenov, E. K. Zaharova, A. L. Vladykin, A. A. Globenko, A. V. Kapashin, K. A. Ishchenko | ||
| "... with Vespireit® 15 mg on an empty stomach once daily for 5 days. During the study, blood samples were collected ..." | ||
| Vol 1, No 3-4 (2009) | TREATMENT FOR ACUTE NONSPECIFIC BACK PAIN IN OUTPATIENT PRACTICE | Abstract similar documents |
| O. N. Gerasimova, V. A. Parfenov | ||
| "... Seventy patients (40 females and 30 males; mean age 46,5±15,0 years) with acute nonspecific back ..." | ||
| Vol 12, No 2 (2020) | Etoricoxib can be used for chronic nonspecific back pain: a new indication of the well-known drug | Abstract similar documents |
| A. E. Karateev | ||
| "... is significantly superior to placebo and that at a dose of 150 mg/day is not inferior to diclofenac. The important ..." | ||
| Vol 16, No 5 (2024) | Gidazepam – daytime tranquilizer for the treatment of anxiety | Abstract similar documents |
| Yu. E. Azimova, D. S. Petelin | ||
| "... and procognitive properties without subsequent exhaustion; the effects of the upper dose range (from 100–150 mg/day ..." | ||
| Vol 5, No 3 (2013) | Analysis of factors influencing the early efficiency of systemic thrombolytic therapy for ischemic stroke | Abstract similar documents |
| Elena Vladimirovna Prazdnichkova, A M Alasheev, O A Shalagina, L I Volkova | ||
| "... in the severity of neurological deficit according to the National Institute of Health Stroke Scale (NIHSS) on day ..." | ||
| Vol 15, No 2 (2023) | Withdrawal of valproic acid during pregnancy in women with epilepsy | Abstract similar documents |
| H. I. Navumava, P. N. Vlasov, A. I. Prusakova, A. A. Usoltseva, N. A. Shnayder, D. V. Dmitrenko | ||
| "... of 32 patients (21.8%) received VA at a dose of <700 mg/day; 10 (31.3%) – 700–1000 mg/day, 15 (46 ..." | ||
| Vol 10, No 3 (2018) | MicroRNA expression profile in patients in the early stages of ischemic stroke | Abstract similar documents |
| I. S. Zhanin, V. A. Gusar, A. T. Timofeeva, V. G. Pinelis, A. Yu. Asanov | ||
| "... miRNAs isolated from the plasma samples of the patients on days 1 and 8 after onset of IS and isolated ..." | ||
| Vol 8, No 2 (2016) | Glatiramer acetate 40 mg/ml: A review of the results of GALA and GLACIER clinical studies | Abstract similar documents |
| N. Yu. Lashch, A. N. Boiko | ||
| "... of treatment with GA 40 mg TIW versus GA 20 mg every day. This study confirmed that the tolerability profile ..." | ||
| Vol 12, No 5 (2020) | The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study | Abstract PDF (Eng) similar documents |
| D. V. Ivashchenko, S. Z. Khoang, M. Kh. Tazagulova, B. V. Makhmudova, N. I. Buromskaya, P. V. Shimanov, R. V. Deitch, I. V. Dorina, M. I. Nastovich, K. A. Akmalova, A. A. Kachanova, E. A. Grishina, L. M. Savchenko, Yu. S. Shevchenko, D. A. Sychev | ||
| "... ) (mean age, 14.83±1.84 years). All the patients took an antipsychotic. The follow-up lasted 28 days ..." | ||
| Vol 13, No 4 (2021) | Postpartum depression — risk factors, clinical and treatment aspects | Abstract similar documents |
| M. A. Makarova, Yu. G. Tikhonova, T. I. Avdeeva, I. V. Ignatko, M. A. Kinkulkina | ||
| "... disorders in women in the postpartum period. Patients and methods. A prospective cohort study included 150 ..." | ||
| Vol 12, No 2 (2020) | Myofascial pain syndrome in female patients with chronic nonspecific back pain: diagnosis and treatment | Abstract similar documents |
| D. O. Rozhkov, O. E. Zinovyeva, A. N. Barinov, I. M. Vikhlyantsev, G. Z. Mikhailova, N. V. Penkov, A. M. Nosovsky | ||
| "... with aceclofenac 200 mg/day in combination with tolperisone 450 mg/day and nondrug therapy (cognitive behavioral ..." | ||
| Vol 7, No 4 (2015) | Topical issues of the efficiency and safety of using the first direct thrombin inhibitor in real clinical practice | Abstract similar documents |
| A. V. Fonyakin | ||
| "... in diabetic patients receiving dabigatran 150 mg twice daily than in those treated with warfarin ..." | ||
| Vol 1, No 1 (2009) | ETORICOXIB: THERAPEUTIC POTENTIAL | Abstract similar documents |
| A. E. Karateev | ||
| "... to 120 mg/day), lower risk of gastrointestinal events, liver damage, and skin and respiratory reactions ..." | ||
| Vol 12, No 3 (2020) | Experience with chondroitin sulfate in the combination therapy of lower back pain | Abstract similar documents |
| O. A. Shavlovskaya, I. D. Romanov, Yu. S. Prokofyeva | ||
| "... days and intramuscular (i.m.) CS every other day in accordance with the scheme: the first three ..." | ||
| Vol 2, No 4 (2010) | Pediatric Tenoten in therapy of childhood nocturnal enuresis | Abstract similar documents |
| G. M. Dzhanumova, A. V. Budkevich, L. B. Ivanov | ||
| "... ) и фенибут (2-я группа - также 18 детей). тенотен детский назначали по 1 таблетке 3 раза в сутки под ..." | ||
| Vol 4, No 1 (2012) | Sustained-release pramipexole in the treatment of Parkinson’s disease | Abstract similar documents |
| Natalia Vladimirovna Fedorova | ||
| "... назначается 1 раз в сутки. К его преимуществам относятся стабилизация концентрации препарата в плазме, 24 ..." | ||
| Vol 17, No 1 (2025) | Thrombolytic therapy with Revelisa in ischemic stroke: results of the PRIMA international multicenter observational study | Abstract similar documents |
| N. A. Shamalov, D. R. Khasanova, S. V. Marchenko, M. A. Soldatov, T. P Alekseeva, O. V. Androfagina, L. N. Antipova, L. I. Anishchenko, E. M. Beketova, A. A. Bulanov, A. V. Gerasimova, N. Kh. Gorst, A. G. Gutsalyuk, T. V. Demin, A. V. Dyudin, U. A. Yelemanov, A. R. Zakaryaeva, N. N. Zinovyeva, S. S. Ziborova, D. N. Kazakov, N. V. Komissarova, I. V. Korobeynikov, K. V. Korovashkova, E. L. Kuzmin, A. A. Kulesh, R. R. Kuliev, A. S. Lebedev, A. L. Lukyanov, V. I. Maksimov, O. I. Mikhaylenko, I. V. Moldavskaya, D. M. Murtazalieva, Yu. S. Mukhamadieva, V. N. Nesterova, D. G. Novikov, S. V. Platunova, E. P. Prudius, R. A. Rayemgulov, V. A. Saskin, A. V. Sinelshchikova, E. A. Strautmanis, V. S. Suryakhin, E. V. Tavlueva, Yu. A. Telyatnik, N. V. Halo, M. S. Cherepyansky, N. A. Marskaya | ||
| "... . Results. An improvement of 4 points or more on the NIHSS scale one day after TLT was observed in 41 ..." | ||
| Vol 10, No 1 (2018) | Treatment of vertigo in elderly patients with chronic cerebrovascular disease | Abstract similar documents |
| S. N. Duma | ||
| "... who took betahistine 48 mg/day, intravenous Mexidol® 5.0 ml for 10 days, then 375 mg tablets daily ..." | ||
| Vol 10, No 3 (2018) | Effect of indapamide/perindopril fixed-dose combination on 24-hour blood pressure and cognitive functions in treatment-naive middle-aged patients with essential arterial hypertension | Abstract similar documents |
| T. M. Ostroumova, V. A. Parfenov, O. D. Ostroumova, E. V. Borisova | ||
| "... антигипертензивной терапии они получали ФК индапамид 1,25 мг/периндоприл 5 мг 1 раз в сутки утром, при необходимости ..." | ||
| Vol 15, No 1 (2023) | Association of sleep disorders with various polymorphic variants of the 5-HTTLPR SNP rs25531 A>G gene in people aged 25–44 | Abstract similar documents |
| V. V. Gafarov, E. A. Gromova, I. V. Gagulin, D. O. Panov, V. N. Maksimov, M. A. Gubina, A. V. Gafarova | ||
| "... =11.397; df=4; p<0.05). In 19.6% of men and 21.5% of women, sleep duration was 6 hours per day, 5 ..." | ||
| Vol 5, No 1 (2013) | Practical aspects of the use of extended-release ropinirole (requip modutab) in the treatment of Parkinson’s disease | Abstract similar documents |
| Oleg Semenovich Levin, V K Datiyeva | ||
| "... . The starting dose of the drug was 2 mg/day in all the cases. Then it was increased once weekly until ..." | ||
| Vol 16, No 1S (2024): Спецвыпуск: Головная боль | Clinical and psychoemotional characteristics of patients with medication overuse headache | Abstract similar documents |
| E. A. Guziy, A. V. Sergeev, G. R. Tabeeva | ||
| "... associated with an increase in the number of days with headache (HA) by 0.33 days per month. In addition ..." | ||
| Vol 12, No 5 (2020) | The use of vortioxetine for depression in patients with Parkinson's disease in the early and advanced stages of the disease | Abstract similar documents |
| I. V. Miliukhina | ||
| "... by mild to moderate depression. Patients and methods. Examinations were made in 150 patients with PD ..." | ||
| Vol 13, No 3 (2021) | Oxcarbazepine as the initial monotherapy of focal epilepsy in adolescents and adults | Abstract similar documents |
| T. N. Pushkar, A. M. Azhigova, P. N. Vlasov, A. B. Kozhokaru | ||
| "... half of patients (52.9%) were prescribed 1200 mg/day of OXC, 12.3% – <1200 mg/day, and only in 6 ..." | ||
| Vol 13, No 6 (2021) | The effect of sleep duration on the risk of diabetes mellitus in an open population of men aged 45–64 years (international epidemiological studies) | Abstract PDF (Eng) similar documents |
| V. V. Gafarov, E. A. Gromova, D. O. Panov, L. V. Shcherbakova, A. N. Tripelgorn, S. K. Malyutina, O. D. Rymar, S. V. Mustafina, I. V. Gagulin, A. V. Gafarova | ||
| "... популяции мужчин 45–64 лет наиболее распространенная продолжительность сна составила 7 ч в сутки (44,7%), на ..." | ||
| Vol 15, No 3 (2023) | Prediction of restoration of swallowing function in patients with ischemic stroke and neurogenic dysphagia | Abstract similar documents |
| A. A. Borzdyko, V. I. Ershov, N. V. Gumalatova, T. Yu. Lozinskaya, E. D. Lutsai | ||
| "... -feeding on the 21st day in groups with dysphagia severity from 105 to 135 points on the MASA scale ..." | ||
| Vol 6, No 3 (2014) | Optimal duration of therapy in the recovery period of vestibular diseases | Abstract similar documents |
| M. V. Zamergrad, V. A. Parfenov, N. N. Yakhno | ||
| "... были осмотрены четыре раза. Регистрировались симптомы и анамнез заболевания. При сборе жалоб ..." | ||
| Vol 11, No 2 (2019) | Nonepileptic myoclonus of infancy and early childhood (an observation of 33 patients) | Abstract PDF (Eng) similar documents |
| O. K. Volkova, A. V. Kalina, G. S. Karpovich, I. V. Volkov | ||
| "... кластеров – до 10 раз в сутки. Количество пароксизмов в кластере – от 2 до 50. Задержка психомоторного ..." | ||
| Vol 11, No 4 (2019) | Clinical experience with piribedil in chronic cerebrovascular disease with cognitive impairment | Abstract similar documents |
| E. V. Moroz, T. A. Zakharycheva, M. V. Antonyuk | ||
| "... и КН прием пирибедила по 50 мг 1 раз в сутки в течение 3 мес способен улучшить когнитивные функции у ..." | ||
| Vol 8, No 4 (2016) | NEUROLOGICAL DISORDERS IN PATIENTS WITH HYPERTENSION AND THEIR CORRECTION | Abstract similar documents |
| N. V. Vakhnina, O. V. Milovanova | ||
| "... Кавинтон® Комфорте по 10 мг 3 раза в сутки. Заключение. Под влиянием терапии наблюдалось уменьшение ..." | ||
| Vol 13, No 5 (2021) | Impact of mental disorders on COVID-19 outcomes | Abstract similar documents |
| N. N. Petrova, V. E. Pashkovskiy, M. S. Sivashova, A. N. Gvozdetsky, G. A. Prokopovich | ||
| "... . The death occurred on 11.5 day. The mental state of these patients was severe, with a predominance ..." | ||
| Vol 7, No 1 (2015) | Possibility of predicting hemorrhagic transformation during reperfusion therapy for ischemic stroke in the patient population of the Sverdlovsk Region | Abstract similar documents |
| E. V. Prazdnichkova, A. M. Alasheev, A. A. Belkin, L. I. Volkova | ||
| "... , on days 1 and 7 after TLT, and when the patient displayed any deterioration in his/her condition. Analysis ..." | ||
| Vol 3, No 3 (2011) | Cognitive functions in late periods after reconstructive operations on the carotid arteries | Abstract similar documents |
| T. P. Evdokimova, N. M. Lobova, L. A. Geraskina, P. A. Fedin, M. N. Guryev, Yu. V. Rodionova, S. I. Skrylev | ||
| "... ischemic changes in 27 (32%) patients on days 1-2. Results and discussion. As compared to the baseline ..." | ||
| Vol 15, No 1 (2023) | New possibilities for the treatment of mild cognitive impairment and prevention of dementia in patients with cerebrovascular disease. Results of the PRIORITET Observation Program | Abstract similar documents |
| E. Y. Solovieva, P. R. Kamchatnov, L. B. Novikova, O. A. Kicherova, N. M. Khasanova | ||
| "... a day during 24 weeks. The presence of MCI was confirmed by testing on the MoCA scale; MI was assessed ..." | ||
| Vol 9, No 1 (2017) | Some risk factors of stroke in dwellers of the Republic of Tyva | Abstract similar documents |
| B. M. Doronin, Kh. D. Mongush | ||
| "... .61% consumed vegetables and fruits every day. The majority of respondents ate not more than once every two ..." | ||
| Vol 6, No 1 (2014) | The use of neurocytoprotectors to improve rehabilitation of patients after cerebrovascular accident | Abstract similar documents |
| V.V. Kovalchuk | ||
| "... received intravenous infusion of Thiocetam at a dose of 30 ml for 14 days, then 1 tablet TID for 1 month ..." | ||
| Vol 1, No 1 (2009) | TENOTEN IN COMPLEX THERAPY FOR CEREBROVASCULAR INSUFFICIENCY IN ELDERLY PATIENTS | Abstract similar documents |
| L. D. Serova | ||
| "... of 20 patients. During 28 days, the study group patients received tenoten as a tablet thrice daily ..." | ||
| Vol 8, No 1 (2016) | Opportunities in multimodal neuroimaging for optimizing thrombolytic therapy for ischemic stroke | Abstract similar documents |
| M. M. Odinak, I. A. Voznyuk, S. N. Yanishevsky, S. Yu. Golokhvastov, N. V. Tsygan, A. Yu. Polushin, R. V. Andreev, D. A. Mirnaya | ||
| "... . With an irreversible tissue damage volume of >60 cm3 on day 1 of stroke, as evidenced by diffusion-weighted MRI ..." | ||
| Vol 16, No 3 (2024) | Analyzing the predictors of relapse in drug-induced headache: a prospective clinical and psychological study | Abstract similar documents |
| E. A. Guziy, A. V. Sergeev, G. R. Tabeeva | ||
| "... of analgesic use per day (OR 15.8; 95% C113.1—23.4), degree of alexithymia (score on TAS-26 scale: OR 11.3; 95 ..." | ||
| 1 - 70 of 304 Items | 1 2 3 4 5 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
